Valuation: Laboratorios Farmaceuticos Rovi, S.A.

Market Cap 2.94B 3.37B 2.7B 2.52B 4.77B 320B 4.86B 32.52B 12.6B 157B 12.64B 12.36B 542B P/E 2026 *
22x
P/E 2027 * 16.6x
Enterprise Value 2.91B 3.33B 2.68B 2.49B 4.73B 317B 4.81B 32.21B 12.48B 156B 12.52B 12.25B 536B EV / Sales 2026 *
3.76x
EV / Sales 2027 * 3.18x
Free-Float
31.63%
Yield 2026 *
1.69%
Yield 2027 * 1.95%
3 years 50.88
Extreme 50.88
90.61
5 years 0.03
Extreme 0.03
90.61
10 years 0.03
Extreme 0.03
90.61
Manager TitleAgeSince
Chief Executive Officer - 2007-07-26
Director of Finance/CFO - 2000-12-31
Chief Tech/Sci/R&D Officer - 2013-12-31
Director TitleAgeSince
Chairman - 2021-07-16
Director/Board Member - 2007-07-26
Director/Board Member - 2007-07-26
Change 5-day change 1-year change 3-year change Capi.($)
-27.31%-.--% - - 3.35B
+1.61%+7.31%+55.29%+162.26% 1,063B
+3.18%+7.12%+68.63%+60.58% 611B
+3.48%+6.83%+36.17%+92.39% 444B
+4.17%-0.96%+26.12%+20.22% 324B
+4.94%+3.39%+39.92%+40.14% 285B
+2.42%+1.60%+30.06%+44.59% 283B
+2.47%+5.18%-24.80%-38.67% 219B
+3.01%+5.59%+25.49%+65.56% 195B
+3.33%+5.14%+16.76%+69.72% 156B
Average +0.18%+2.83%+30.40%+57.42% 397.85B
Weighted average by Cap. +2.88%+4.16%+41.14%+82.76%

Financials

2026 *2027 *
Net sales 774M 886M 711M 663M 1.26B 84.33B 1.28B 8.56B 3.32B 41.36B 3.33B 3.25B 143B 898M 1.03B 825M 769M 1.46B 97.86B 1.48B 9.93B 3.85B 48B 3.86B 3.78B 165B
Net income 133M 152M 122M 114M 216M 14.49B 220M 1.47B 570M 7.11B 571M 559M 24.49B 178M 203M 163M 152M 288M 19.35B 293M 1.96B 761M 9.49B 763M 747M 32.7B
Net Debt -27.87M -31.9M -25.59M -23.87M -45.25M -3.04B -46.01M -308M -119M -1.49B -120M -117M -5.13B -85.9M -98.3M -78.88M -73.56M -139M -9.36B -142M -950M -368M -4.59B -369M -361M -15.82B
Logo Laboratorios Farmaceuticos Rovi, S.A.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows: - prescription pharmaceuticals (49%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.; - pharmaceutical products manufactured under contract (44%); - diagnostic products (7%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals. Net sales break down by source of revenue between sales of products (95.4%) and sales of services (4.6%). Net sales are distributed geographically as follows: Spain (77%), Italy (5%), Germany (3%), Portugal (2%), France (1%), Greece (1%) and other (11%).
Employees
1,998
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
57.50EUR
Average target price
75.38EUR
Spread / Average Target
+31.09%

Quarterly revenue - Rate of surprise